Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer
<i>Background</i>: Stereotactic body radiotherapy (SBRT) is a recognized treatment for colorectal cancer (CRC) metastases. We postulated that local responses could be improved by SBRT with a concomitant radiosensitizing agent (irinotecan). <i>Methods</i>: RADIOSTEREO-CAMPTO w...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/2/248 |
| _version_ | 1797413035991629824 |
|---|---|
| author | Loïg Vaugier Xavier Mirabel Isabelle Martel-Lafay Séverine Racadot Christian Carrie Véronique Vendrely Marc-André Mahé Hélène Senellart Jean-Luc Raoul Loïc Campion Emmanuel Rio |
| author_facet | Loïg Vaugier Xavier Mirabel Isabelle Martel-Lafay Séverine Racadot Christian Carrie Véronique Vendrely Marc-André Mahé Hélène Senellart Jean-Luc Raoul Loïc Campion Emmanuel Rio |
| author_sort | Loïg Vaugier |
| collection | DOAJ |
| description | <i>Background</i>: Stereotactic body radiotherapy (SBRT) is a recognized treatment for colorectal cancer (CRC) metastases. We postulated that local responses could be improved by SBRT with a concomitant radiosensitizing agent (irinotecan). <i>Methods</i>: RADIOSTEREO-CAMPTO was a prospective multi-center phase 2 trial investigating SBRT (40–48 Gy in 4 fractions) for liver and/or lung inoperable CRC oligometastases (≤3), combined with two weekly intravenous infusions of 40 mg/m<sup>2</sup> Irinotecan. Primary outcome was the objective local response rate as per RECIST. Secondary outcomes were early and late toxicities, EORTC QLQ-C30 quality of life, local control and overall survival. <i>Results</i>: Forty-four patients with 51 lesions (liver = 39, lungs = 12) were included. Median age was 69 years (46–84); 37 patients (84%) had received at least two prior chemotherapy treatments. Median follow-up was 48.9 months. One patient with two lung lesions was lost during follow-up. Assuming maximum bias hypothesis, the objective local response rate in ITT was 86.3% (44/51—95% CI: [76.8–95.7]) or 82.4% (42/51—95% CI: [71.9–92.8]). The observed local response rate was 85.7% (42/49—95% CI: [75.9–95.5]). The 1 and 2-year local (distant) progression-free survivals were 84.2% (38.4%) and 67.4% (21.3%), respectively. The 1 and 2-year overall survivals were 97.5% and 75.5%. There were no severe acute or late reactions. The EORTC questionnaire scores did not significantly worsen during or after treatment. <i>Conclusions</i>: SBRT with irinotecan was well tolerated with promising results despite heavily pretreated patients. |
| first_indexed | 2024-03-09T05:11:44Z |
| format | Article |
| id | doaj.art-26458a60687846c4b719f6f50239ad73 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T05:11:44Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-26458a60687846c4b719f6f50239ad732023-12-03T12:48:09ZengMDPI AGCancers2072-66942021-01-0113224810.3390/cancers13020248Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal CancerLoïg Vaugier0Xavier Mirabel1Isabelle Martel-Lafay2Séverine Racadot3Christian Carrie4Véronique Vendrely5Marc-André Mahé6Hélène Senellart7Jean-Luc Raoul8Loïc Campion9Emmanuel Rio10Department of Radiation Oncology, Institut de Cancérologie de l’Ouest, 44800 St-Herblain, FranceDepartment of Radiation Oncology, Centre Oscar Lambret, 59000 Lille, FranceDepartment of Radiation Oncology, Institut Léon Bérard, 69008 Lyon, FranceDepartment of Radiation Oncology, Institut Léon Bérard, 69008 Lyon, FranceDepartment of Radiation Oncology, Institut Léon Bérard, 69008 Lyon, FranceDepartment of Radiation Oncology, Centre Hospitalo-Universitaire Hôpital Saint André, 33000 Bordeaux, FranceDepartment of Radiation Oncology, Institut de Cancérologie de l’Ouest, 44800 St-Herblain, FranceDepartment of Medical Oncology, Institut de Cancérologie de l’Ouest, 44800 St-Herblain, FranceDepartment of Medical Oncology, Institut de Cancérologie de l’Ouest, 44800 St-Herblain, FranceDepartment of Biostatistics, Institut de Cancérologie de l’Ouest, 44800 St-Herblain, FranceDepartment of Radiation Oncology, Institut de Cancérologie de l’Ouest, 44800 St-Herblain, France<i>Background</i>: Stereotactic body radiotherapy (SBRT) is a recognized treatment for colorectal cancer (CRC) metastases. We postulated that local responses could be improved by SBRT with a concomitant radiosensitizing agent (irinotecan). <i>Methods</i>: RADIOSTEREO-CAMPTO was a prospective multi-center phase 2 trial investigating SBRT (40–48 Gy in 4 fractions) for liver and/or lung inoperable CRC oligometastases (≤3), combined with two weekly intravenous infusions of 40 mg/m<sup>2</sup> Irinotecan. Primary outcome was the objective local response rate as per RECIST. Secondary outcomes were early and late toxicities, EORTC QLQ-C30 quality of life, local control and overall survival. <i>Results</i>: Forty-four patients with 51 lesions (liver = 39, lungs = 12) were included. Median age was 69 years (46–84); 37 patients (84%) had received at least two prior chemotherapy treatments. Median follow-up was 48.9 months. One patient with two lung lesions was lost during follow-up. Assuming maximum bias hypothesis, the objective local response rate in ITT was 86.3% (44/51—95% CI: [76.8–95.7]) or 82.4% (42/51—95% CI: [71.9–92.8]). The observed local response rate was 85.7% (42/49—95% CI: [75.9–95.5]). The 1 and 2-year local (distant) progression-free survivals were 84.2% (38.4%) and 67.4% (21.3%), respectively. The 1 and 2-year overall survivals were 97.5% and 75.5%. There were no severe acute or late reactions. The EORTC questionnaire scores did not significantly worsen during or after treatment. <i>Conclusions</i>: SBRT with irinotecan was well tolerated with promising results despite heavily pretreated patients.https://www.mdpi.com/2072-6694/13/2/248colorectal cancerstereotactic radiotherapyoligometastasesirinotecanliver metastaseslung metastases |
| spellingShingle | Loïg Vaugier Xavier Mirabel Isabelle Martel-Lafay Séverine Racadot Christian Carrie Véronique Vendrely Marc-André Mahé Hélène Senellart Jean-Luc Raoul Loïc Campion Emmanuel Rio Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer Cancers colorectal cancer stereotactic radiotherapy oligometastases irinotecan liver metastases lung metastases |
| title | Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer |
| title_full | Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer |
| title_fullStr | Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer |
| title_full_unstemmed | Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer |
| title_short | Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer |
| title_sort | radiosensitizing chemotherapy irinotecan with stereotactic body radiation therapy for the treatment of inoperable liver and or lung metastases of colorectal cancer |
| topic | colorectal cancer stereotactic radiotherapy oligometastases irinotecan liver metastases lung metastases |
| url | https://www.mdpi.com/2072-6694/13/2/248 |
| work_keys_str_mv | AT loigvaugier radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer AT xaviermirabel radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer AT isabellemartellafay radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer AT severineracadot radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer AT christiancarrie radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer AT veroniquevendrely radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer AT marcandremahe radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer AT helenesenellart radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer AT jeanlucraoul radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer AT loiccampion radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer AT emmanuelrio radiosensitizingchemotherapyirinotecanwithstereotacticbodyradiationtherapyforthetreatmentofinoperableliverandorlungmetastasesofcolorectalcancer |